30 results about "Dimethylbenzimidazole" patented technology

The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and / or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex, dragons blood, mace, sage and red sandalwood with at least c) one compound capable of maximizing oxidative mitochondrial function preferably riboflavin or vitamin B2 derivatives, FAD, FMN, 5-amino-6-(5′-phosphoribitylamino)uracil, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, niacin, vitamin C and pantothenate and / or d) at least one lactic acid dehydrogenase inhibitor (preferably 2′,3,4′5,7-pentahydroxyflavone) and optionally f) an alkalizing agent (aloe vera, chlorella, wheat grass, sodium or potassium bicarbonate, potassium) g) an antiproliferative herb (speranskia or goldenseal) and h) a pharmaceutically acceptable carrier.

The invention describes a nutraceutical composition and method for preventing / treating cancer comprised of A) quinones (2,3-dimethoxy-5-methyl-1,4-benzoquinone, thymoquinone, tocopherolquinone) B) compounds capable of maximizing oxidative mitochondrial function preferably riboflavin, FAD, FMN, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, B3, C and pantothenate C) lactic acid dehydrogenase inhibitors; 2′,3,4′5,7-pentahydroxyflavone, epigallocatechin gallate, quercetin, citric acid, rosemary, black walnut, clove, nutmeg, licorice root, coriander, cinnamon, ginger root, myrrh gum and green tea D) alkalizing agents: aloe vera, chlorella, wheat grass, apple cider vinegar, burdock root, kudzu root, alfalfa, barley grass, spirulina, parsley leaf, calcium, magnesium, potassium or bicarbonate salts E) potent tumoricidal herbs; gromwell root, wild yam, beth root, teasel root, balm of gilead bud, frankincense, bakuchi seed, dichroa root, kochia seed, kanta kari, sweet myrrh, galbanum, garcinia fruit, mace, white sage and tumoricial plant derived constituents: gambogic acid, shikonin, diosmin or boswellic acid F) an antiproliferative herb (speranskia or goldenseal) and G) a pharmaceutically acceptable carrier.

The invention describes a nutraceutical composition and method for preventing / treating cancer or augmenting chemotherapy in advanced stage malignancies; comprised of [1] tumoricidal herbs; beth root, galbanum, gromwell root, wild yam, balm of gilead bud, frankincense, [2] an antiproliferative herb; speranskia [3] a natural lactic acid dehydrogenase (LDH) inhibitor, 2′,3,4′5,7-pentahydroxyflavone or cinnamon, [4] alkalizing agents: calcium, magnesium, potassium or bicarbonate salts, barley grass, chlorella and spirulina [5] at least one quinone and [6] at least one agent capable of maximizing oxidative mitochondrial function preferably riboflavin, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin and a pharmaceutically acceptable carrier.

The invention discloses a 5-substituted dihydrobenzofuran-imidazolium salt compound and a preparation method thereof. The preparation method comprises the following steps of: performing Vilsmeier reaction by taking 2,3-dihydrobenzofuran as a raw material, thereby synthesizing 5-carboxaldehyde dihydrobenzofuran, reducing the 5-carboxaldehyde dihydrobenzofuran into 5-benzyl alcohol substituted dihydrobenzofuran in an alcohol by using sodiumborohydride, and then converting the 5-benzyl alcohol substituted dihydrobenzofuran into methanesulfonate, next, carrying out a reflux reaction between the methanesulfonate and imidazolium or benzimidazole in a solvent, thereby synthesizing 1-(substituted dihydrobenzofuran) imidazolium, and finally, on the basis, reacting the 1-(substituted dihydrobenzofuran) imidazolium with a halide to synthesize the 5-substituted dihydrobenzofuran-imidazolium salt compound. According to the invention, a pharmacophore with remarkable anti-tumor activity in a natural product is used as a precursor and then design and synthesis of anti-tumor medicine molecules are carried out, and consequently, the synthesized compound has excellent in-vitro anti-tumorous cytotoxin activity. Researches show that the compound has excellent in-vitro anti-cancer biological activity when the imidazolium structure unit is 5,6-dimethyl benzimidazole and the substituent group thereof on the site of 3 is 2-bromobenzyl, naphthoyl methyl or 4-bromophenacyl.

The invention relates to a preparation method of a polybenzimidazole-structure-similar two-dimensional covalent organic framework, belonging to the technical field of the preparation of covalent organic frameworks. The invention aims at providing the preparation method of the two-dimensional covalent organic framework which is taken as a novel phosphoric acid PBI system. The preparation method comprises the steps of adding 2,5-diamino-3,4-dimethylbenzimidazole and trialdehyde triphenol into an ampoule bottle in a molar ratio of 3 to 2, adding a solvent and a catalyst into the ampoule bottle, carrying out liquid nitrogen freezing degassing-unfreezing-freezing degassing for three cycles, sealing a pipe by virtue of a flame gun, putting the ampoule bottle into a 120-DEG C drying oven, reacting for 3-5 days, opening the pipe, filtering and collecting solid products in the pipe, carrying out Soxhlet extraction on the solid product through tetrahydrofuran, and carrying out vacuum drying at the room temperature, so as to obtain the polybenzimidazole-structure-similar two-dimensional covalent organic framework. The two-dimensional covalent organic framework prepared by virtue of the preparation method has a good microcellular structure.

The invention belongs to the technical field of biological fermentation, and discloses a method for producing vitamin B12 by using Pseudomonas aeruginosa based on pH value control. The method for producing the vitamin B12 by using the Pseudomonas aeruginosa based on the pH value control comprises the steps that a production strain of vitamin B12, namely the Pseudomonas aeruginosa is inoculated into a fermentation medium, and fermentation is carried out at a temperature of 25-30 DEG C; the composition of the fermentation medium comprises 70-85g / L of cane molasses, 90-110g / L of yeast extract, 0.05-0.2 g / L of 5,6-dimethylbenzimidazole, 0.1-1g / L of glycerophosphoric acid, 0.05-2g / L of cobalt chloride, 0.05-0.2g / L of urea, 10-30g / L of betaine, 0.05-0.2 g / L of arginine, 0.01-0.5g / L of thiamine and the like; the pH value of fermentation broth is controlled at 7 by the cane molasses and the urea; and the purified vitamin B12 is separated from the fermentation broth. The yield of the vitamin B12 is improved by controlling the pH in the fermentation process.

The invention discloses a method for synthesizing 1-difluoromethyl imidazole and a derivative thereof. The method is characterized in that ethyl bromodifluoroacetate, a substrate iminazole and a derivative thereof and alkali are dissolved in a reaction solvent, the mixed liquid is heated and stirred, a difluoromethylation reaction happens, and the substrate is benzimidazole, 2-phenyl benzimidazole, 5-nitrobenzimidazole, 5,6-dimethyl benzimidazole, imidazole, 2-methylimidazole and 2-ethyl imidazole. Ethyl bromodifluoroacetate is adopted as a difluoromethylation reagent, no ozone is consumed, environmental friendliness is achieved, the whole reaction condition is mild and aftertreatment is simple.

The invention discloses a series of 2-aryl-3-methyl benzofuran-benzimidazole salt compound with a structure general formula (such as formula I or II) and a preparation method thereof. The preparation method comprises the following steps: taking salicylic aldehyde as a raw material and synthesizing benzylide salicylic aldehyde with 4-substituted benzyl bromide in anhydrous DMF; then synthesizing 2-aryl-3-methyl benzofuran in phosphorus oxychloride and the anhydrous DMF; successively synthesizing 2-aryl-3-methanol benzofuran with sodium borohydride in methanol; finally firstly synthesizing methanesulfonate with methanesulfonyl chloride in dichloromethane, then synthesizing 2-aryl-3-methyl benzofuran-benzimidazole with benzimidazole or 5,6-dimethyl benzimidazole in methylbenzene and on the basis, synthesizing the 2-aryl-3-methyl benzofuran-benzimidazole salt compound with brominated alkanes in methylbenzene. The compound shows better antitumor cytotoxic activity.

The invention relates to a method for detecting the content of 5,6-dimethyl benzimidazole. The method is characterized in that a high-performance liquid chromatography is adopted for detection. As the high-performance liquid chromatography is adopted for detecting the content of 5,6-dimethyl benzimidazole, no strongly-corrosive and strongly-irritant solvent used in a titration method exists, and the safety and reliability are achieved; the content of 5,6-dimethyl benzimidazole in a sample is quantified according to an external standard method, so that the method provided by the invention is accurate, simple, and high in repeatability and sensitivity; a relatively good linear relationship is formed when the 5,6-dimethyl benzimidazole is between 0.1-2.0 mg / ml, and the linear correlation coefficient is 0.9996.

The invention discloses a series of isomannide-bis-benzimidazole salt compounds having a structural general formula (as in figure 1) and a preparation method thereof; isomannide, as a raw material, and 4-toluene sulfonyl chloride are converted into isomannide p-toluenesulfonate under dichloromethane and anhydrous pyridine, the isomannide p-toluenesulfonate and benzimidazole or 5,6-dimethylbenzimidazole are subjected to thermal reaction in anhydrous DMF (dimethylformamide) solvent to synthesize isomannide-bis-benzimidazole, and on such basis, the isomannide-bis-benzimidazole and alkyl bromide are subjected to reflux reaction in acetonitrile solvent to synthesize isomannide-bis-benzimidazole salt compounds. Results of in-vitro antitumor active cytotoxicity test indicate that part of the compounds have good cytotoxicity.

The invention discloses a series of N-alkyl substituted indole-imidazolium salt compounds having a structural formula (represented b figure I), and a preparation method thereof. The preparation method comprises the following steps: synthesizing N-alkyl substituted indole from indole used as a raw material and dibromoalkane in an anhydrous DMF solvent, carrying out a heating reaction on the N-alkyl substituted indole and 5,6-dimethylbenzimidazole in a toluene solvent to synthesize N-alkyl substituted indole-imidazole, and carrying out a refluxing reaction on the N-alkyl substituted indole-imidazole and bromoalkane in the toluene solvent to synthesize the N-alkyl substituted indole-imidazolium salt compounds. The compounds have good anti-tumor cytotoxicity activity.

The invention discloses a preparation method and application of biphenyl bridged bis-benzimidazolium. 1,3-dimethyl benzimidazolium iodate and 1,4-diiodobiphenyl as substrates, a metal salt as a catalyst and an alkali as an additive are subjected to reaction at 0-200 DEG C for 0.1-96 hours to obtain biphenyl bridged bis-benzimidazolium via one step. The compound biphenyl bridged bis-benzimidazoliumis dissolved in acetonitrile; a little quality of the obtained solution is injected between two ITO (indium tin oxide) glass sheets; a voltage is applied; the solution turns from no color to coffee;the voltage is removed, and the solution turns colorless; the color variation process is irreversible many times. The preparation method has the advantages that, for instance, the process is simple, operation is convenient, the cost is low, and the preparation method is environmentally friendly and good in repeatability; it is expected to achieve industrial large-scale production. The imidazoliumderivative with electrochromic property is synthesized herein and is expectedly applicable to the fields, such as electronic displays, variable color glass, and automotive anti-dazzling rearview mirrors.

The invention discloses a group of plasma metabolism markers related to intracranial aneurysm and application of the plasma metabolism markers. The markers comprise oxidized glutathione, reduced glutathione, methyl beta-D-galactopyranoside, koji disaccharide, D-pinose, dopaquinone, indoleacetaldehyde, 5, 5 '-dihydroxyacetophenone, beta-glucopyranosyl-beta-D-glucopyranosyl-beta-D-glucopyranosyl-beta-D-glucopyranosyl The reagent is prepared from 2, 6-dimethylbenzimidazole, N-palmitoyl glycine, uracil, indole-3-acetic acid and 1-acetyl indole. According to the invention, the plasma is used as a detection object, and the sample is noninvasive and easier to obtain, can be used for large-scale screening, is beneficial to early diagnosis and dynamic monitoring of intracranial aneurysm, and reduces huge risks brought to patients by rupture of intracranial aneurysm; small molecule metabolites are used as diagnostic markers, and the detection method is simple, can be used in the field of rapid diagnosis, and is good in detection specificity and high in accuracy; compared with protein and gene as disease diagnosis markers, the method has superiority.

The invention relates to a synthetic method of 2-n-propyl-4-methylbenzimidazole-6-carboxylic acid. The synthetic method comprises the following steps: through nitric acid / concentrated sulfuric acid nitrification reaction of 3,5-dimethylnitrobenzene, generating an intermediate product II, namely 3,5-dimethyl-1,2-dinitrobenzene; performing Pd / C catalytic hydrogenation reaction on the intermediate product II in an ethanol solution to obtain an intermediate product III, namely 3,5-dimethyl-1,2-phenylenediamine; enabling the intermediate product III to react with N-butyric acid in a polyphosphoric acid solution to obtain an intermediate product IV, namely 2-n-propyl-4,6-dimethylbenzimidazole; performing cobalt salt air liquid-phase oxidation reaction on the intermediate product IV in an acetic acid solution to obtain a product V, namely the 2-n-propyl-4-methylbenzimidazole-6-carboxylic acid. The synthetic method provided by the invention has the benefits that the operation is simple, raw materials are easy to obtain, a used solvent can be recycled, the product content can reach 95 percent or above, the yield is up to 73.2 percent, the pollution is less, and the suitability for industrial production is realized.

The invention discloses a method for synthesizing 1-difluoromethyl imidazole and a derivative thereof. The method is characterized in that ethyl bromodifluoroacetate, a substrate iminazole and a derivative thereof and alkali are dissolved in a reaction solvent, the mixed liquid is heated and stirred, a difluoromethylation reaction happens, and the substrate is benzimidazole, 2-phenyl benzimidazole, 5-nitrobenzimidazole, 5,6-dimethyl benzimidazole, imidazole, 2-methylimidazole and 2-ethyl imidazole. Ethyl bromodifluoroacetate is adopted as a difluoromethylation reagent, no ozone is consumed, environmental friendliness is achieved, the whole reaction condition is mild and aftertreatment is simple.

The invention discloses a series of isomannide-bis-benzimidazole salt compounds having a structural general formula (as in figure 1) and a preparation method thereof; isomannide, as a raw material, and 4-toluene sulfonyl chloride are converted into isomannide p-toluenesulfonate under dichloromethane and anhydrous pyridine, the isomannide p-toluenesulfonate and benzimidazole or 5,6-dimethylbenzimidazole are subjected to thermal reaction in anhydrous DMF (dimethylformamide) solvent to synthesize isomannide-bis-benzimidazole, and on such basis, the isomannide-bis-benzimidazole and alkyl bromide are subjected to reflux reaction in acetonitrile solvent to synthesize isomannide-bis-benzimidazole salt compounds. Results of in-vitro antitumor active cytotoxicity test indicate that part of the compounds have good cytotoxicity.

The invention discloses a 11, 12-dimethyl benzimidazole-1, 8-naphthalimide-platinum complex and a preparation method and application thereof. The preparation method of the complex mainly comprises: putting compounds shown in the formulas (II) and (III) into an organic solvent, and performing a coordination reaction process under heating or no heating to obtain a desired product. Compared with thecommon antitumor drug cisplatin, the complex has higher inhibitory activity to some cancer cells and lower toxicity to human liver normal cells HL-7702. The structure of the complex is shown in the formula (I). The raw materials for preparation of the complex are shown in the formulas (II) and (III).

The invention discloses a benzimidazole binuclear zinc metal complex and an application of the complex in a PVC (polyvinyl chloride) thermal stabilizer. The benzimidazole binuclear zinc metal complex Zn2L2(H2PO3)4 is prepared by the following steps: firstly, by using m-phthalic acid and 4, 5-dimethyl o-phenylenediamine as an initial raw material and polyphosphoric acid as a solvent and a catalyst, preparing a benzimidazole ligand 1, 3-di(2-(5, 6-dimehtyl benzimidazole)) benzene (ligand L); and preparing the complex by means of a simple solution method. By using the benzimidazole binuclear zinc metal complex Zn2L2(H2PO3)4 as a main raw material which is supplemented with other co-stabilizers to prepare a compound stabilizer, and the compound stabilizer is added into PVC to synergically improve the thermal stability of PVC. For 100 parts of PVC by weight, the additive amount of the complex is 0.2-3.5 parts by weight, preferably 0.5-1.5 parts by weight. The thermal stabilizer disclosed by the invention is convenient to prepare, can be used for improving the stainability of PVC and the long-term thermal stability, and has a good application prospect.

A composition can include a Rho zeolite with a RHO topology having a Si to B ratio or a Si to Al ratio greater than or equal to 8. Making such a composition can include heating an aqueous reaction mixture having a molar ratio of atomic Si to atomic B of about 4 to about 50 or a molar ratio of atomic Si to atomic Al of about 4 to about 50 in the presence of a C4-C6 diquat of N,2-dimethylbenzimidazole structure directing agent to a temperature of at least 75 deg C to produce a Rho zeolite.

A composition can include a Rho zeolite with a RHO topology having a Si to B ratio or a Si to A1 ratio greater than or equal to 8. Making such a composition can include heating an aqueous reaction mixture having a molar ratio of atomic Si to atomic B of about 4 to about 50 or a molar ratio of atomic Si to atomic Al of about 4 to about 50 in the presence of a C4-C6 diquat of N,2-dimethylbenzimidazole structure directing agent to a temperature of at least 75° C. to produce a Rho zeolite.

The invention discloses a preparation method of 5, 6-dimethyl benzimidazole. The preparation method comprises the following four steps: preparation of N-(3, 4-dimethyl phenyl) formamide, preparation of N-(4, 5-dimethyl-2-nitrophenyl) formamide, preparation of N-(2-amino-4, 5-dimethyl phenyl) formamide, and preparation of 5, 6-dimethyl benzimidazole. The preparation method has the following beneficial effects: 1, acetylation and deacetylation used in the prior art are avoided, which is in favor of environmental protection; 2, the synthesis steps of the process are shortened, the original five-step reaction is shortened to the present four-step reaction, and the yield is improved; and 3, the purity of the intermediate is high, separation is not needed, the operation is simple, the defects and deficiencies of the preparation method reported in the literature are overcome, and the method has novelty, greater positive progress effect and practical application value.

The invention discloses a 11, 12-dimethyl benzimidazole-1, 8-naphthalimide-platinum complex and a preparation method and application thereof. The preparation method of the complex mainly comprises: putting compounds shown in the formulas (II) and (III) into an organic solvent, and performing a coordination reaction process under heating or no heating to obtain a desired product. Compared with thecommon antitumor drug cisplatin, the complex has higher inhibitory activity to some cancer cells and lower toxicity to human liver normal cells HL-7702. The structure of the complex is shown in the formula (I). The raw materials for preparation of the complex are shown in the formulas (II) and (III).

The invention relates to a series of chalcone-benzimidazole salt compounds with a general structural formula (as shown in a figure I which is described in the specification). According to the invention, 3,4,5-trimethoxybenzaldehyde and hydroxyacetophenone are used as raw materials and subjected to an aldol condensation reaction in a solvent consisting of ethanol and water in ratio of 4: 1 under the catalysis of the catalyst NaOH so as to produce a compound with a chalcone structure; then the compound reacts with 1,3-dibromopropane in ultra-dry DMF at room temperature to produce a brominated chalcone intermediate; and the brominated chalcone intermediate separately reacts with benzimidazole, 2-methylbenzimidazole and 5,6-dimethylbenzimidazole in a toluene solvent under the catalysis of thecatalyst Et3N to produce benzimidazole compositions, and the benzimidazole compositions react with brominated substances in an acetone solvent to synthesize the novel chalcone-benzimidazole salt compounds. Good in-vitro antitumor activity is obtained when a substituent, located at the position 3, of 5,6-dimethylbenzimidazole is a menaphthyl group.

The invention discloses a series of N-alkyl substituted indole-imidazolium salt compounds having a structural formula (represented b figure I), and a preparation method thereof. The preparation method comprises the following steps: synthesizing N-alkyl substituted indole from indole used as a raw material and dibromoalkane in an anhydrous DMF solvent, carrying out a heating reaction on the N-alkyl substituted indole and 5,6-dimethylbenzimidazole in a toluene solvent to synthesize N-alkyl substituted indole-imidazole, and carrying out a refluxing reaction on the N-alkyl substituted indole-imidazole and bromoalkane in the toluene solvent to synthesize the N-alkyl substituted indole-imidazolium salt compounds. The compounds have good anti-tumor cytotoxicity activity.

The invention discloses a metal complex catalyst and a synthesis process of diphenyl carbonate. The metal complex catalyst comprises a main active component and a carrier, wherein the main active component is loaded on the carrier; the main active component comprises a copper complex and / or a cobalt complex; the copper complex is CuL < 2 > X < 2 >, and the cobalt complex is Co < L > 'X < 2 >; wherein L is N, N-dimethyl benzimidazole (NN-DBDMID), L' is diimine diphosphine (PNNP), and X in the copper complex and X in the cobalt complex are respectively and independently negative ions. The metal complex catalyst disclosed by the invention has the advantages of high catalytic activity, high diphenyl carbonate selectivity, low cost, difficulty in corrosion of a reactor and the like; a process for catalytically synthesizing diphenyl carbonate by using the metal complex catalyst has the advantages of high product yield, simple process, cheap and easily available raw materials, no pollution, safety and capability of greatly reducing the explosion risk.

The invention discloses a series of isosorbide-monoimidazole salt compounds with a structural formula (as shown in a figure I or figure II) and a preparation method of the isosorbide-monoimidazole salt compounds. The preparation method includes: adopting isosorbide as a raw material, performing reaction with methylsulfonyl chloride under an anhydrous pyridine condition to obtain isosorbide methanesulfonate, subjecting to thermal reaction with 2-methylimidazole or 5,6-dimethyl benzimidazole in an anhydrous DMF (dimethyl formamide) solvent to synthesize isosorbide-monoimidazole, and performing reflux reaction with alkyl bromide in a methylbenzene solvent to synthesize the isosorbide-monoimidazole salt compounds. The isosorbide-monoimidazole salt compounds show great analgesic effects.

The present invention provides a pyrenylbenzimidazole fluorescent probe and its preparation method and application. The fluorescent probe has the structure shown in formula (I), and its preparation process is as follows: (1) 1, 2-di Tolylbenzimidazole and (3-bromopropyl) dimethyl ammonium bromide are added to acetonitrile, and heated to reflux, after the reaction is completed, compound A is isolated; (2) compound A and 1-pyrene formaldehyde are Heating to reflux in ethanol, after separation and purification, the fluorescent probe with the structure shown in formula (I) was obtained. The fluorescent probe of the invention can be used for the detection of heparin, and has the characteristics of simple synthesis, good water solubility, long luminescent wavelength, high sensitivity to heparin, strong selectivity, dual-mode response and wide application range.

The invention discloses a series of isosorbide-monoimidazole salt compounds with a structural formula (as shown in a figure I or figure II) and a preparation method of the isosorbide-monoimidazole salt compounds. The preparation method includes: adopting isosorbide as a raw material, performing reaction with methylsulfonyl chloride under an anhydrous pyridine condition to obtain isosorbide methanesulfonate, subjecting to thermal reaction with 2-methylimidazole or 5,6-dimethyl benzimidazole in an anhydrous DMF (dimethyl formamide) solvent to synthesize isosorbide-monoimidazole, and performing reflux reaction with alkyl bromide in a methylbenzene solvent to synthesize the isosorbide-monoimidazole salt compounds. The isosorbide-monoimidazole salt compounds show great analgesic effects.

The invention provides a pyrenyl benzimidazole fluorescent probe and a preparation method and application thereof. The pyrenyl benzimidazole fluorescent probe is of a structure shown in the formula (I), and the preparation process of the pyrenyl benzimidazole fluorescent probe comprises the following steps: (1) adding 1,2-dimethyl benzimidazole and (3-bromopropyl)dimethyl ammonium bromide into acetonitrile, conducting heating reflux, and after the reaction is completed, conducting separation to obtain a compound A; and (2) heating and refluxing the compound A and 1-pyrenecarboxaldehyde in ethanol, and conducting separating and purifying to obtain the fluorescent probe with the structure as shown in the formula (I). The fluorescent probe disclosed by the invention can be used for detecting heparin, and has the characteristics of simplicity in synthesis, good water solubility, long light-emitting wavelength, high sensitivity to heparin, strong selectivity, dual-mode response and wide application range.

The invention discloses a preparation method and application of biphenyl bridged bisbenzimidazolium. Using 1,3-dimethylbenzimidazolium iodide and 1,4-diiodobiphenyl as substrates, metal salts as catalysts, and bases as additives, react at 0-200°C for 0.1-96 hours, One-step biphenyl bridged bis-benzimidazolium. Dissolve the compound in acetonitrile, inject a small amount of the resulting solution between two pieces of ITO glass, apply a voltage, the solution changes from colorless to brown, remove the voltage, and the solution becomes colorless again, this discoloration process is reversible and can be repeated repeatedly. The invention has the advantages of simple process, convenient operation, low cost, environmental friendliness, good repeatability, etc., and is expected to realize industrialized large-scale production; the invention synthesizes an imidazolium derivative with electrochromic properties, which is expected to be applied to electronic Display, color-changing glass, automotive anti-glare rearview mirror and other fields.